PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01723774 |
Recruitment Status :
Active, not recruiting
First Posted : November 8, 2012
Results First Posted : June 2, 2022
Last Update Posted : December 8, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Neoplasms | Drug: PD0332991 Drug: Anastrozole Drug: Goserelin Procedure: Surgery (standard of care) Procedure: Tumor biopsy | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 84 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer |
Actual Study Start Date : | April 10, 2013 |
Actual Primary Completion Date : | April 13, 2021 |
Estimated Study Completion Date : | April 30, 2027 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1: PIK3CA Wild Type Cohort
|
Drug: PD0332991 Drug: Anastrozole Other Name: Arimidex® Drug: Goserelin Other Names:
Procedure: Surgery (standard of care) -Breast and axillary lymph node surgery Procedure: Tumor biopsy |
Experimental: Arm 2: PIK3CA Mutant Type Cohort
|
Drug: PD0332991 Drug: Anastrozole Other Name: Arimidex® Drug: Goserelin Other Names:
Procedure: Surgery (standard of care) -Breast and axillary lymph node surgery Procedure: Tumor biopsy |
Experimental: Arm 3: Endocrine Resistant Cohort
|
Drug: PD0332991 Drug: Anastrozole Other Name: Arimidex® Drug: Goserelin Other Names:
Procedure: Surgery (standard of care) -Breast and axillary lymph node surgery Procedure: Tumor biopsy |
- Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (PIK3CA Wild Type Cohort Only) [ Time Frame: At cycle 1 day 15 (2 weeks) ]Complete cell cycle arrest is defined as Ki67 ≤ 2.7% following 2 weeks of neoadjuvant PD 0332991
- Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (Endocrine Resistant Cohort Only) [ Time Frame: At cycle 1 day 15 (2 weeks) ]Complete cell cycle arrest is defined as Ki67 ≤ 2.7% following 2 weeks of neoadjuvant PD 0332991
- Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 ( PIK3CA Mutant Type Cohort Only) [ Time Frame: At cycle 1 day 15 (2 weeks) ]Complete cell cycle arrest is defined as Ki67 ≤ 2.7% following 2 weeks of neoadjuvant PD 0332991
- Number of Participants With Complete Cell Cycle Arrest [ Time Frame: Cycle 1 day 1 and cycle 1 day 15 (2 weeks) ]Compare rate of complete cell cycle arrest (defined as Ki67 ≤ 2.7%) arrest between C1D1 and C1D15
- Clinical Response Rate [ Time Frame: 16 weeks ]
- The clinical response rate is the number of patients whose disease meets the WHO criteria of complete or partial response prior to surgery divided by the total number of eligible patients who began combination neoadjuvant treatment.
- Complete Response (CR) is defined as the disappearance of all known disease based on a comparison between the pre-treatment measurements and the measurements taken at the completion of neo-adjuvant therapy (that is, at the end of cycle 4 neo-adjuvant combination therapy). In addition there is no appearance of new lesions.
- Partial Response (PR) is defined as a 50% or greater decrease in the product of the bidimensional measurements of the lesion (total tumor size) between the pre-treatment measurements and the measurements taken at the completion of neo-adjuvant therapy (that is, at the end of cycle 4 neo-adjuvant combination therapy). In addition there can be no appearance of new lesions or progression of any lesion.
- Radiologic Response Rate [ Time Frame: At the end of cycle 4 prior to surgery (estimated to be 16 weeks) ]
- The radiological response rate is the number of patients whose disease meets with WHO criteria for complete or partial response at the evaluation prior to surgery divided by the total number of eligible patients who began combination neo-adjuvant therapy.
- Complete Response (CR) is defined as the disappearance of all known disease based on a comparison between the pre-treatment measurements and the measurements taken at the completion of neo-adjuvant therapy (that is, at the end of cycle 4 neo-adjuvant combination therapy). In addition there is no appearance of new lesions.
- Partial Response (PR) is defined as a 50% or greater decrease in the product of the bidimensional measurements of the lesion (total tumor size) between the pre-treatment measurements and the measurements taken at the completion of neo-adjuvant therapy (that is, at the end of cycle 4 neo-adjuvant combination therapy). In addition there can be no appearance of new lesions or progression of any lesion.
- Safety of PD 0332991 in Combination in Anastrozole as Measured by Frequency and Grade of Related Adverse Events [ Time Frame: From start of treatment through 30 days after completion of an estimated 4 months of neoadjuvant therapy ]The maximum grade for each type of adverse event will be recorded for each patient using the NCI-CTCAE v4.0 coding scheme, and frequency tables will be reviewed to determine patterns. Additionally, the relationship (possibly related, probably related, and definitely related) of the adverse event(s) to the study treatment will be taken into consideration.
- Number of Participants With a PEPI-0 Score [ Time Frame: At the time of surgery (estimated to be 5 months) ]
- Preoperative endocrine prognostic index (PEPI) score is derived from four factors assigned a numerical score following neoadjuvant endocrine therapy, including Ki67 expression in the surgical specimen, pathologic tumor size (indicated as "T" below), lymph node status (indicated as "N" below), and estrogen receptor (ER) level (indicated as ER Allred below).
- PEPI-0 score indicates T1 or T2, N0, Ki67 < 2.7%, ER Allred > 2.
- It predicts a low risk of recurrence.
- Change in Ki67 Level of Tumor Specimens [ Time Frame: Pre-treatment and cycle 1 day 15 ]To assess Ki67 level on serially collected tumor specimens
- Change in Ki67 Level of Tumor Specimens [ Time Frame: Cycle 1 day 15 and at time of surgery (approximately 2-4 weeks post completion of cycle 4 - each cycle is 28 days) ]To assess Ki67 level on serially collected tumor specimens
- Number of Participants With Pathologic Complete Response (pCR) [ Time Frame: At the time of surgery (estimated to be 5 months) ]-A pathologic complete response is defined as no histology evidence of invasive tumor cells in the surgical breast specimen and sentinel or axillary lymph nodes.
- Safety Profile of Study Therapy During Adjuvant Therapy as Measured by Frequency and Grade of Adverse Event [ Time Frame: From start of adjuvant therapy through 30 days after completion of adjuvant therapy (estimated to be 2 years) ]The maximum grade for each type of adverse event will be recorded for each patient using the NCI-CTCAE v4.0 coding scheme, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.
- Overall Survival [ Time Frame: 5 years ]
- Relapse-free Survival [ Time Frame: 5 years ]
- Local Recurrence Rate [ Time Frame: 5 years ]Local recurrence is defined as histologic evidence of ductal carcinoma in situ or invasive breast cancer in the ipsilateral breast or chest wall.
- Regional Recurrence Rate [ Time Frame: 5 years ]Regional recurrence is defined as the cytologic or histologic evidence of disease in the ipsilateral internal mammary, ipsilateral supraclavicular, ipsilateral infraclavicular and/or ipsilateral axillary nodes or soft tissue of the ipsilateral axilla.
- Distant Recurrence Rate [ Time Frame: 5 years ]Distant recurrence is defined as the cytologic, histologic, and/or radiographic evidence of disease in the skin, subcutaneous tissue, lymph nodes (other than local or regional metastasis), lung, bone narrow, central nervous system or histologic and/or radiographic evidence of skeletal or liver metastasis.
- Rate of Second Primary Breast Cancer [ Time Frame: 5 years ]Second primary breast cancer is defined histologic evidence of ductal carcinoma in situ or invasive breast cancer in the contralateral breast or chest wall.
- Rate of Second Primary Cancer (Non-breast) [ Time Frame: 5 years ]Second primary cancer (non-breast) is defined as any non-breast second primary cancer other than squamous or basal cell carcinoma of the skin, melanoma in situ, or carcinoma in situ of the cervix is to be reported and should be confirmed histologically whenever possible.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Pre-registration PIK3CA Mutant Inclusion
- Clinical T2-T4c, any N, M0 invasive ER+ (Allred Score of 6-8) and HER2 negative (0 or 1+ by IHC or FISH negative for amplification) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node. Note: Patients with invasive ER+ (Allred Score of 6-8) HER2- breast cancer or DCIS in the contralateral breast the patient are eligible
- Female ≥18 years of age
- ECOG performance status of 0, 1 or 2
- Life expectancy > 4 months
- Premenopausal, patient must be willing to comply with pregnancy requirements
-
Adequate organ and marrow function
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) < 2.5 X ULN
- Creatinine ≤ ULN
- Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Prior treatment of this cancer including: surgery, radiation, chemotherapy, biotherapy, hormonal therapy, investigational agent prior to study entry
- Receiving any investigational agents
- Prior therapy with any Cdk4 inhibitor
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy
- Evidence of inflammatory cancer
- Known metastatic disease
- Current use of anticoagulation therapy
- Previous excisional biopsy of the breast cancer or sentinel lymph node biopsy
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
Registration PIK3CA Mutant Inclusion The criteria below must be met in addition to the pre-registration criteria, except treatment with endocrine therapy for this cancer is allowed prior to registration
- PIK3CA mutant cohort: tumor PIK3CA mutation present
- Premenopausal women, serum estradiol level in postmenopausal range ≤ 7 days prior to registration
Exclusion Criteria below must be met in addition to the pre-registration criteria -Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
PIK3CA Wild Type Inclusion
- Clinical T2-T4c, any N, M0 invasive ER+ (Allred Score of 6-8) and HER2 negative (0 or 1+ by IHC or FISH negative for amplification) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node. Note: Patients with invasive ER+ (Allred Score of 6-8) HER2- breast cancer or DCIS in the contralateral breast the patient are eligible
- For the PIK3CA wild type cohort: tumor PIK3CA mutation absent. Note that if a patient did not have sufficient research tissue for PIK3CA sequencing at pre-registration or if PIK3CA sequencing result is delayed, she could be registered and enrolled on the PD991 trial without assigning to a particular cohort at the time of enrollment. PIK3CA sequencing will be performed in the future on tumors collected at subsequent time points to assign the treatment cohort or when the PIK3CA sequencing data is available
-
For the endocrine resistant cohort: Ki67 > 10% by central testing at Washington University AMP laboratory from a tumor biopsy performed after at least 2 weeks on neoadjuvant endocrine therapy. Note that prior neoadjuvant endocrine therapy could include any endocrine therapy (including aromatase inhibitor, tamoxifen, fulvestrant) alone or in combination, or endocrine therapy in combination with any investigational agent that is not a Cdk 4/6 inhibitor
*Patients who had a Day 17 Ki67 > 10% from the NCI9170 trial are eligible for the endocrine resistant cohort
- Female >18 years of age
- ECOG performance status of 0, 1 or 2
- Life expectancy > 4 months
- If premenopausal, patient must be willing to comply with pregnancy requirements
-
Adequate organ and marrow function:
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) < 2.5 X ULN
- Creatinine ≤ ULN
- In premenopausal women, serum estradiol level in postmenopausal range ≤ 7 days prior to registration.
- Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Prior treatment of this cancer including: Surgery, Radiation therapy, Chemotherapy, Biotherapy, Hormonal therapy, Investigational agent prior to study entry
- Receiving any other investigational agents
- Prior therapy with any Cdk4 inhibitor
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy
- Evidence of inflammatory cancer
- Known metastatic disease
- Current use of anticoagulation therapy
- Previous excisional biopsy of the breast cancer or sentinel lymph node biopsy
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
- Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
Endocrine Resistant Inclusion
- Clinical T2-T4c at diagnosis or screening, any N, M0 invasive ER+ (Allred Score at least 3 or > 1% ER positivity) and HER2 negative (0 or 1+ by IHC or FISH negative or equivocal) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node. Note: Patients with invasive breast cancer that is ER pos, HER2 neg or equivocal or DCIS in the contralateral breast are eligible; multi-focal diseases are not excluded. The dominant lesion will be followed per protocol
- Ki67 > 10% by central testing at Washington University AMP laboratory from a tumor biopsy performed after at least 2 weeks on neoadjuvant endocrine therapy. If Ki67 is > 10% by local testing, the Ki67 slide and H&E slide need to be reviewed by the study pathologist to confirm eligibility (discuss with Study Chair). For patients external to Washington University, please contact the Washington University coordinator by email so that a screening ID# can be assigned prior to shipment of the slides
- Female ≥ 18 years of age
- ECOG performance status of 0, 1 or 2
- Pre- or post-menopausal women are eligible. If premenopausal, patient must be willing to comply with pregnancy requirements and agrees with GnRH agonist therapy for ovarian suppression during the study
-
Adequate organ and marrow function:
- Leukocytes ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) < 2.5 X ULN
- Creatinine ≤ ULN
- Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Prior treatment of this cancer including: Surgery, Radiation, Chemotherapy
- Receiving any other investigational agents
- Prior therapy with Cdk4 inhibitor
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy
- Known metastatic disease
- Current use of anticoagulation therapy
- Previous excisional biopsy of the breast cancer or sentinel lymph node biopsy
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
- Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
Adjuvant Inclusion
- Derived benefit from PD 0332991 in the neoadjuvant setting in this trial. This includes the 26 patients who achieved complete cell cycle arrest only after the addition of PD 0332991 (C1D1 Ki67 >2.7% and C1D15 Ki67 ≤ 2.7%) from the main study (PIK3CA WT, mutant, or unknown cohorts) as well as any patients who have a Ki67 ≤ 10% on C1D15 biopsy in the endocrine resistant cohort
- ECOG performance status of 0, 1 or 2
- Premenopausal, patient must be willing to comply with pregnancy requirements laid out
-
Adequate organ and marrow function
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) ≤ 2.5 X ULN
- Creatinine ≤ ULN
- Underwent surgery of the breast and axilla for curative intent
- At least 4 weeks post completion of adjuvant chemotherapy and radiation therapy if indicated
-
Patients who already started on adjuvant hormonal therapy are eligible under the following conditions:
- For the 26 patients who enrolled in the initial cohorts and derived benefit from neoadjuvant PD 0332991 (C1D1 Ki67 >2.7% and C1D15 Ki67 ≤ 2.7%), adjuvant PD 0332991 should be initiated as soon as possible if adjuvant hormonal therapy has been initiated and the patient has completed radiation if indicated
- For patients who enrolled in the endocrine resistant cohort and derived benefit from neoadjuvant PD 0332991 (C1D15 Ki67 ≤ 10%), adjuvant PD 0332991 should be initiated within 6 months or sooner after initation of adjuvant hormonal therapy
- Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, ssychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy. -Known metastatic disease
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
- Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01723774
United States, Alabama | |
University of Alabama | |
Birmingham, Alabama, United States, 35233 | |
United States, Arizona | |
Mayo Clinic - Scottsdale | |
Scottsdale, Arizona, United States, 85259 | |
United States, Minnesota | |
Mayo Clinic - Rochester | |
Rochester, Minnesota, United States, 55905 | |
United States, Missouri | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63122 |
Principal Investigator: | Cynthia X Ma, M.D., Ph.D. | Washington University School of Medicine |
Documents provided by Washington University School of Medicine:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT01723774 |
Other Study ID Numbers: |
201301106 |
First Posted: | November 8, 2012 Key Record Dates |
Results First Posted: | June 2, 2022 |
Last Update Posted: | December 8, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Anastrozole Goserelin Palbociclib Antineoplastic Agents, Hormonal Antineoplastic Agents |
Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Protein Kinase Inhibitors |